Bionano Genomics Announces its Participation at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting with Six Posters and All of its On-Market Solutions on Display
- Bionano is back in-person at the ACMG annual meeting – this time as ONE COMPANY with MORE SOLUTIONS
- For the first time, Bionano will exhibit all of its products and solutions with its combined commercial teams together [in one location]
- Optical Genome Mapping Solutions,
- Testing and Laboratory Services, &
- Software
- Six scientific posters will illustrate the capabilities and scope of Bionano’s solutions for impacting clinical genetics research and rare undiagnosed genetic diseases (RUGD)
The main ACMG conference sessions take place from March 23–26, 2022, in
“Bionano has evolved significantly in the last two years and we are now one team with more solutions that can benefit genetic clinicians and researchers. We believe our solutions can promote discovery by enabling geneticists to see more important genetic variations, and our testing services can play a role in ending the diagnostic odyssey for patients with genetic disorders. We are eager to showcase the ways in which we can partner with geneticists in our continued mission to transform how the world sees the genome,” said Erik Holmlin, PhD, President and CEO of Bionano Genomics.
Scientific poster session contributions from Bionano and collaborators include:
Poster Title | Poster number | Author list (Presenting author highlighted) | |||
Optical Genome Mapping Workflow for Constitutional Genomic Structural and Copy Number Variation and Analysis | eP334 | Clifford B, Barseghyan H, Pang AWC, Chaubey A, Hastie A | |||
Comparative Benchmarking of Optical Genome Mapping and Chromosomal Microarray Reveals High Technological Concordance in CNV Identification and Structural Variant Refinement |
eP317 |
Barseghyan H, Pang AWC, Sulpizio S, Morton A, Chaubey A, Hastie A | |||
Optical Genome Mapping for High Throughput Analysis of Repeat Expansion Disorders | eP379 |
Muggli M, Ramandi B, Miller N, Zhang D, Lam ET, Wang J, Wang T, Lee J, Pang AWC, Sadowski HB, Hastie A, Oldakowski M | |||
Optical Genome Mapping Capability Expanded to Enable Detection of Absence of Heterozygosity | eP388 | Rao AR, Lam ET, Velazquez-Muriel JA, Zhang D, Miller N, Pang AWC, Hastie A, Chaubey A, Oldakowski M | |||
The Full (Mutation) Picture: One-Third of Patients with Fragile X Syndrome Present with Neurodevelopmental Disorders without Dysmorphism or Family History | eP341 |
Diaz J, Lovelace E, Ortega A, Martin M | |||
Optical Genome Mapping for Constitutional Postnatal SV, CNV, and Repeat Array Sizing: A Multi-site Clinical Study | eP391 | Sahajpal N, Kolhe R |
Full content of the posters will be made available on the
About
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the ability of our comprehensive solutions to benefit genetic clinician and researchers, including by promoting discovery and enabling geneticists to see important genetic variations; the ability of our testing services to play a role in providing diagnostic answers to patients with genetic disorders; and our ability to partner with geneticists in its continued mission to transform how the world sees the genome. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements in existing technologies; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support additional studies, adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
+1 (858) 366-3243
amy@juniper-point.com
Source: Bionano Genomics